Why the study?
Although the novel Resolute Onyx zotarolimus-eluting stent is used in daily practice, no clinical results had been published beyond 2 years.
Does the Resolute Onyx zotarolimus-eluting stent (RO-ZES) improve TVF compared to the Orsiro sirolimus-eluting stent (O-SES)?
Does the Resolute Onyx zotarolimus-eluting stent (RO-ZES) improve TVF compared to the Orsiro sirolimus-eluting stent (O-SES)?
At 3 years, the Resolute Onyx zotarolimus-eluting stent demonstrated comparable efficacy and safety to the Orsiro sirolimus-eluting stent.
Answers are grounded in this paper and cite their sources.
RO-ZES matches O-SES for 3-year TVF with a nonsignificant mortality trend; confirms long-term comparability of these DES platforms.
BACKGROUND: At 1 year, the international randomized BIONYX trial (ClinicalTrials.gov:NCT02508714) established non-inferiority regarding safety and efficacy of the novel Resolute Onyx zotarolimus-eluting stent (RO-ZES) vs. the Orsiro sirolimus-eluting stent (O-SES). Although the RO-ZES is used in daily practice, no clinical results have been published beyond 2 years. METHODS AND CONCLUSIONS: This first 3-year randomized assessment of the RO-ZES showed a favorable rate of TVF that matched the outcomes of patients treated with O-SES. We observed a lower rate of all-cause death in the RO-ZES group, but long-term clinical follow-up is of interest.
No takes yet. Share an insight, caveat, or question.
Ploumen et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: